Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Oaktree Specialty Lending Corp is a credit services business based in the US. Oaktree Specialty Lending shares (OCSL) are listed on the NASDAQ and all prices are listed in US Dollars.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $6.48 |
|---|---|
| 52-week range | $6.02 - $7.45 |
| 50-day moving average | $6.99 |
| 200-day moving average | $7.29 |
| Wall St. target price | $8.14 |
| PE ratio | 9.3333 |
| Dividend yield | $0.59 (10.25%) |
| Earnings per share (TTM) | $0.69 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.48 from 2022-06-29
| 1 week (2022-06-23) | 2.53% |
|---|---|
| 1 month (2022-05-27) | -7.69% |
| 3 months (2022-03-30) | -12.31% |
| 6 months (2021-12-30) | -13.14% |
| 1 year (2021-06-30) | -3.14% |
|---|---|
| 2 years (2020-06-30) | 44.97% |
| 3 years (2019-06-28) | 19.56% |
| 5 years (2017-06-30) | 33.33% |
Valuing Oaktree Specialty Lending stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Oaktree Specialty Lending's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Oaktree Specialty Lending's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, Oaktree Specialty Lending shares trade at around 9x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Oaktree Specialty Lending's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9343. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Oaktree Specialty Lending's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $258.5 million |
|---|---|
| Operating margin TTM | 69.07% |
| Gross profit TTM | $209.4 million |
| Return on assets TTM | 4.3% |
| Return on equity TTM | 10.54% |
| Profit margin | 53.18% |
| Book value | $7.26 |
| Market capitalisation | $1.2 billion |
TTM: trailing 12 months
Dividend payout ratio: 89.29% of net profits
Recently Oaktree Specialty Lending has paid out, on average, around 89.29% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 10.25% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Oaktree Specialty Lending shareholders could enjoy a 10.25% return on their shares, in the form of dividend payments. In Oaktree Specialty Lending's case, that would currently equate to about $0.59 per share.
Oaktree Specialty Lending's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Oaktree Specialty Lending's most recent dividend payout was on 29 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 13 June 2022 (the "ex-dividend date").
Over the last 12 months, Oaktree Specialty Lending's shares have ranged in value from as little as $6.0219 up to $7.4466. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oaktree Specialty Lending's is 1.3444. This would suggest that Oaktree Specialty Lending's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oaktree Specialty Lending Corporation is a business development company specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity and management buyouts in small and mid-sized companies. It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering, and media and advertising sectors. It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies with enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million. The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America. The fund seeks to be a lead investor in its portfolio companies. .
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.